Meeting on NDC changes
Executive Summary
FDA will hold a public meeting Dec. 11 to discuss proposed changes to the National Drug Code system contained in an August proposed rule governing drug establishment registration and listing. The proposed revisions would reorganize and modify regulations on who must list human drugs and biologics and require that the appropriate NDC number appear on the labels of all drugs subject to the listing requirements. The meeting will be held from 9 a.m. to 4 p.m. at 5630 Fishers Lane, Rockville, Md. FDA has also extended the deadline for submitting comments on the rule to Jan. 26...
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.